

**P&T Motion History
Newer Antiplatelet Motion**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<p>clopidogrel/ ASA dipyridamole ASA/ ER prasugrel ticagrelor ticlopidine/ ASA vorapaxar</p>	<p>After considering the evidence of safety, efficacy and special populations for the treatment of acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), and peripheral vascular disease, I move that clopidogrel, ticagrelor and prasugrel are safe and efficacious for the treatment of their approved indications. The antiplatelets cannot be subject to therapeutic interchange in the Washington preferred drug list. At this time vorapaxar is included on the PDL as a non-preferred drug. Motion: Rowe 2nd: Klingel</p> <p>After considering the evidence of safety, efficacy and special populations for the treatment of stroke and transient ischemic attack, I move that extended release dipyridamole*aspirin and clopidogrel are safe and efficacious. Extended release dipyridamole*aspirin and clopidogrel cannot be subject to therapeutic interchange in the Washington preferred drug list for the treatment of stroke and transient ischemic attack. I move that ticlopidine products not be put on the PDL due to safety concerns.</p>	<p>October 18, 2017</p>	<p>NA</p>	<p>Yes Figuroa Storhaug</p>	<p>Passed unanimous</p>

Bold = new drug

* New drugs excluded from OHSU review

10/19/2017